On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

A large European study finds that TNF inhibitors work differently across joints in psoriatic arthritis, with the shoulder and ...